Eszopiclone - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for eszopiclone and what is the scope of freedom to operate?
Eszopiclone
is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Chartwell Rx, Dr Reddys, Glenmark Pharms Ltd, Hetero Labs Ltd V, Hikma, Ipca Labs Ltd, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Nostrum Labs Inc, Orbion Pharms, Sun Pharm, Teva, and Waylis Therap, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.There are twenty drug master file entries for eszopiclone. Thirty-five suppliers are listed for this compound.
Summary for eszopiclone
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 15 |
NDAs: | 15 |
Drug Master File Entries: | 20 |
Finished Product Suppliers / Packagers: | 35 |
Raw Ingredient (Bulk) Api Vendors: | 60 |
Clinical Trials: | 71 |
Patent Applications: | 6,596 |
Drug Prices: | Drug price trends for eszopiclone |
Drug Sales Revenues: | Drug sales revenues for eszopiclone |
What excipients (inactive ingredients) are in eszopiclone? | eszopiclone excipients list |
DailyMed Link: | eszopiclone at DailyMed |
Recent Clinical Trials for eszopiclone
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, Los Angeles | Phase 2 |
National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
Siriraj Hospital | Phase 4 |
Medical Subject Heading (MeSH) Categories for eszopiclone
Anatomical Therapeutic Chemical (ATC) Classes for eszopiclone
Paragraph IV (Patent) Challenges for ESZOPICLONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LUNESTA | Tablets | eszopiclone | 1 mg, 2 mg and 3 mg | 021476 | 10 | 2008-12-15 |
US Patents and Regulatory Information for eszopiclone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Pharms Ltd | ESZOPICLONE | eszopiclone | TABLET;ORAL | 091166-001 | Apr 15, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-001 | Dec 15, 2004 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Teva | ESZOPICLONE | eszopiclone | TABLET;ORAL | 091169-003 | May 23, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Dr Reddys | ESZOPICLONE | eszopiclone | TABLET;ORAL | 091024-003 | Apr 15, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-002 | Dec 15, 2004 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for eszopiclone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-003 | Dec 15, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-001 | Dec 15, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-001 | Dec 15, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-002 | Dec 15, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-002 | Dec 15, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |